CN107519479B - Soluble powder containing enterobacter peptide and preparation method thereof - Google Patents
Soluble powder containing enterobacter peptide and preparation method thereof Download PDFInfo
- Publication number
- CN107519479B CN107519479B CN201710985369.6A CN201710985369A CN107519479B CN 107519479 B CN107519479 B CN 107519479B CN 201710985369 A CN201710985369 A CN 201710985369A CN 107519479 B CN107519479 B CN 107519479B
- Authority
- CN
- China
- Prior art keywords
- enterobacter
- peptide
- cyclodextrin
- beta
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses a soluble powder containing enterobacter peptide, which comprises the following components in parts by weight per 100 parts of medicine: 1-10 parts of enterobacter peptide, 1-20 parts of beta-cyclodextrin and the balance of water-soluble starch; the enterobacter peptide is a metabolite of Escherichia coli ZNYT2, wherein the Escherichia coli ZNYT2 is preserved in the common microorganism center of China Committee for culture Collection of microorganisms, and the preservation unit is abbreviated as: CGMCC, storage unit address: west road No.1 hospital No. 3, north jing, chaoyang district, preservation date: 2016, 8, 23 days, accession number: CGMCC NO.12902, Classification name: escherichia coli. The invention adopts an inclusion technology, and performs inclusion treatment on the enterobacter peptide by utilizing beta-cyclodextrin and water-soluble starch, thereby increasing the solubility of the enterobacter peptide on one hand and increasing the stability of the polypeptide drug on the other hand.
Description
Technical Field
The invention belongs to the technical field of biological peptide, and particularly relates to soluble powder containing enterobacter peptide and a preparation method thereof.
Background
In recent years, with the use of a large amount of antibiotics, bacterial drug resistance is continuously formed, so that the curative effect of the existing antibacterial drugs on bacterial infection treatment is low or ineffective, and the formed harm is increasingly serious. How to overcome the drug resistance of bacteria is the focus and hot spot of current research, researchers are trying to search for new antibacterial strategies, and there is an urgent need to develop novel antibacterial agents. The antibacterial peptide which has high efficiency, low toxicity and difficult drug resistance formation is concerned by researchers at home and abroad as a new medicine preparation which is hopeful to replace antibiotics.
The agricultural Yinggtai biological peptide Limited company in Linzhou aims at screening bacterial strains for producing antibacterial peptides resisting gram-negative bacteria, 25 bacterial strains with antibacterial activity are screened out through outdoor sampling and primary screening of the bacterial strains, a bacterial strain with good antibacterial activity is obtained through multiple rounds of secondary screening, and the bacterial strain is identified to be probiotic escherichia coli ECN. Meanwhile, some property evaluation and strain mutagenesis are carried out on the antibacterial substance generated by the strain, so that the antibacterial peptide producing capability of the strain is greatly improved, and the application requirement of industrial production can be met.
The enterobacter peptide has wide antibacterial range and obvious effect of treating intestinal diseases of livestock and poultry. Aiming at the medication mode of livestock and poultry, the oral administration is convenient and easy, and the cost is lower. Because the water solubility of the enterobacter peptide is poor and is influenced by factors such as external conditions, temperature, pH value and the like, the oral preparation has certain limitation.
Disclosure of Invention
The invention aims to solve the technical problems that the water solubility of enterobacter peptide is poor, the enterobacter peptide is influenced by factors such as external conditions, temperature, pH value and the like, and the enterobacter peptide-containing soluble powder prepared by the method has certain limitation.
The object of the invention is achieved in the following way:
the soluble powder containing the enterobacter peptide comprises the following components in parts by weight per 100 parts of medicine: 1-10 parts of enterobacter peptide, 1-20 parts of beta-cyclodextrin and the balance of water-soluble starch.
The enterobacter peptide is a metabolite of Escherichia coli ZNYT2, and the Escherichia coli ZNYT2 is preserved in the common microorganism center of China Committee for culture Collection of microorganisms, wherein the preservation unit is abbreviated as: CGMCC, storage unit address: west road No.1 hospital No. 3, north jing, chaoyang district, preservation date: 2016, 8, 23 days, accession number: CGMCC number 12902, taxonomic nomenclature: escherichia coli.
The preparation method of the soluble powder containing the enterobacter peptide comprises the following specific steps:
(1) preparing ethanol water solution with volume fraction of 10-20%;
(2) weighing enterobacter peptide and beta-cyclodextrin according to the formula ratio, wherein the mass ratio of the beta-cyclodextrin to water in the ethanol water solution prepared in the step (1) is 1 (5-7);
(3) placing the ethanol aqueous solution prepared in the step (1) into a stirring tank, wherein the temperature is 40-60 ℃, under the stirring condition, firstly dissolving beta-cyclodextrin in the ethanol aqueous solution, then adding enterobacter peptides into the ethanol aqueous solution, stirring for 10-30min, and cooling to room temperature;
(4) freeze-drying the ethanol water solution containing the enterobacter peptide and the beta-cyclodextrin obtained in the step (3) for 8-12 h;
(5) mixing the freeze-dried inclusion compound obtained in the step (4) with water-soluble starch, and then crushing to obtain powder with the granularity of 60-80 meshes;
(6) mixing, and packaging to obtain soluble powder of enterobacter peptide.
Compared with the prior art, the invention adopts an inclusion technology, and performs inclusion treatment on the enterobacter peptide by utilizing beta-cyclodextrin and water-soluble starch, thereby increasing the solubility of the enterobacter peptide on one hand and increasing the stability of the polypeptide drug on the other hand.
Drawings
Fig. 1 is a graph comparing solubility curves.
Detailed Description
Example 1:
the soluble powder containing the enterobacter peptide comprises the following components in parts by weight per 100 parts of medicine: 1-10 parts of enterobacter peptide, 1-20 parts of beta-cyclodextrin and the balance of water-soluble starch.
The enterobacter peptide is a metabolite of Escherichia coli ZNYT2, and the Escherichia coli ZNYT2 is preserved in the common microorganism center of China Committee for culture Collection of microorganisms, wherein the preservation unit is abbreviated as: CGMCC, storage unit address: west road No.1 hospital No. 3, north jing, chaoyang district, preservation date: 2016, 8, 23 days, accession number: CGMCC number 12902, taxonomic nomenclature: escherichia coli.
The preparation method of the soluble powder containing the enterobacter peptide comprises the following specific steps:
(1) preparing ethanol water solution with volume fraction of 10-20%;
(2) weighing enterobacter peptide and beta-cyclodextrin according to the formula ratio, wherein the mass ratio of the beta-cyclodextrin to water in the ethanol water solution prepared in the step (1) is 1 (5-7);
(3) placing the ethanol aqueous solution prepared in the step (1) into a stirring tank, wherein the temperature is 40-60 ℃, under the stirring condition, firstly dissolving beta-cyclodextrin in the ethanol aqueous solution, then adding enterobacter peptides into the ethanol aqueous solution, stirring for 10-30min, and cooling to room temperature;
(4) freeze-drying the ethanol water solution containing the enterobacter peptide and the beta-cyclodextrin obtained in the step (3) for 8-12 h;
(5) mixing the freeze-dried inclusion compound obtained in the step (4) with water-soluble starch, and then crushing to obtain powder with the granularity of 60-80 meshes;
(6) mixing, and packaging to obtain soluble powder of enterobacter peptide.
Example 2:
a soluble powder containing enterobacter peptide comprises the following components in weight per 100g of medicine: 1g of enterobacter peptide, 1g of beta-cyclodextrin and the balance of water-soluble starch.
The enterobacter peptide is a metabolite of Escherichia coli ZNYT2, wherein the Escherichia coli ZNYT2 is preserved in the common microorganism center of China Committee for culture Collection of microorganisms, and the preservation unit is abbreviated as: CGMCC, storage unit address: west road No.1 hospital No. 3, north jing, chaoyang district, preservation date: 2016, 8, 23 days, accession number: CGMCC number 12902, taxonomic nomenclature: escherichia coli.
The preparation method of the soluble powder containing the enterobacter peptide comprises the following specific steps:
(1) preparing an ethanol water solution with the volume fraction of 10%;
(2) weighing enterobacter peptide and beta-cyclodextrin according to the formula ratio, wherein the mass ratio of the beta-cyclodextrin to water in the ethanol water solution prepared in the step (1) is 1: 5;
(3) placing the ethanol aqueous solution prepared in the step (1) into a stirring tank, wherein the temperature is 40 ℃, under the stirring condition, firstly dissolving beta-cyclodextrin in the ethanol aqueous solution, then adding the enterobacter peptides into the ethanol aqueous solution, stirring for 10min, and cooling to room temperature;
(4) freeze-drying the ethanol water solution containing the enterobacter peptide and the beta-cyclodextrin obtained in the step (3) for 8 hours;
(5) mixing the freeze-dried inclusion compound obtained in the step (4) with water-soluble starch, and then crushing to obtain a powder with the granularity of 60 meshes;
(6) mixing, and packaging to obtain soluble powder of enterobacter peptide.
Example 3:
a soluble powder containing enterobacter peptide comprises the following components in weight per 100g of medicine: 2g of enterobactin peptide, 5g of beta-cyclodextrin and the balance of water-soluble starch.
The enterobacter peptide is a metabolite of Escherichia coli ZNYT2, wherein the Escherichia coli ZNYT2 is preserved in the common microorganism center of China Committee for culture Collection of microorganisms, and the preservation unit is abbreviated as: CGMCC, storage unit address: west road No.1 hospital No. 3, north jing, chaoyang district, preservation date: 2016, 8, 23 days, accession number: CGMCC number 12902, taxonomic nomenclature: escherichia coli.
The preparation method of the soluble powder containing the enterobacter peptide comprises the following specific steps:
(1) preparing an ethanol aqueous solution with the volume fraction of 12%;
(2) weighing enterobacter peptide and beta-cyclodextrin according to the formula ratio, wherein the mass ratio of the beta-cyclodextrin to water in the ethanol water solution prepared in the step (1) is 1: 5.5;
(3) placing the ethanol aqueous solution prepared in the step (1) into a stirring tank, at the temperature of 44 ℃, dissolving beta-cyclodextrin into the ethanol aqueous solution under the stirring condition, adding the enterobacter peptides into the ethanol aqueous solution, stirring for 14min, and cooling to room temperature;
(4) freeze-drying the ethanol water solution containing the enterobacter peptide and the beta-cyclodextrin obtained in the step (3) for 9 hours;
(5) mixing the freeze-dried inclusion compound obtained in the step (4) with water-soluble starch, and then crushing to obtain a particle size of 64 meshes;
(6) mixing, and packaging to obtain soluble powder of enterobacter peptide.
Example 4:
a soluble powder containing enterobacter peptide comprises the following components in weight per 100g of medicine: 4g of enterobacter peptide, 10g of beta-cyclodextrin and the balance of water-soluble starch.
The enterobacter peptide is a metabolite of Escherichia coli ZNYT2, wherein the Escherichia coli ZNYT2 is preserved in the common microorganism center of China Committee for culture Collection of microorganisms, and the preservation unit is abbreviated as: CGMCC, storage unit address: west road No.1 hospital No. 3, north jing, chaoyang district, preservation date: 2016, 8, 23 days, accession number: CGMCC number 12902, taxonomic nomenclature: escherichia coli.
The preparation method of the soluble powder containing the enterobacter peptide comprises the following specific steps:
(1) preparing an ethanol aqueous solution with the volume fraction of 14%;
(2) weighing enterobacter peptide and beta-cyclodextrin according to the formula ratio, wherein the mass ratio of the beta-cyclodextrin to water in the ethanol aqueous solution prepared in the step (1) is 1: 6;
(3) placing the ethanol aqueous solution prepared in the step (1) into a stirring tank, wherein the temperature is 48 ℃, under the stirring condition, firstly dissolving beta-cyclodextrin in the ethanol aqueous solution, then adding the enterobacter peptides into the ethanol aqueous solution, stirring for 18min, and cooling to room temperature;
(4) carrying out freeze-drying treatment on the ethanol water solution containing the enterobacter peptide and the beta-cyclodextrin obtained in the step (3) for 10 hours;
(5) mixing the freeze-dried inclusion compound obtained in the step (4) with water-soluble starch, and then crushing to obtain a particle size of 68 meshes;
(6) mixing, and packaging to obtain soluble powder of enterobacter peptide.
Example 5:
a soluble powder containing enterobacter peptide comprises the following components in weight per 100g of medicine: 6g of enterobacter peptide, 12g of beta-cyclodextrin and the balance of water-soluble starch.
The enterobacter peptide is a metabolite of Escherichia coli ZNYT2, wherein the Escherichia coli ZNYT2 is preserved in the common microorganism center of China Committee for culture Collection of microorganisms, and the preservation unit is abbreviated as: CGMCC, storage unit address: west road No.1 hospital No. 3, north jing, chaoyang district, preservation date: 2016, 8, 23 days, accession number: CGMCC number 12902, taxonomic nomenclature: escherichia coli.
The preparation method of the soluble powder containing the enterobacter peptide comprises the following specific steps:
(1) preparing an ethanol aqueous solution with the volume fraction of 16%;
(2) weighing enterobacter peptide and beta-cyclodextrin according to the formula ratio, wherein the mass ratio of the beta-cyclodextrin to water in the ethanol water solution prepared in the step (1) is 1: 6.5;
(3) placing the ethanol aqueous solution prepared in the step (1) into a stirring tank, wherein the temperature is 52 ℃, under the stirring condition, firstly dissolving beta-cyclodextrin in the ethanol aqueous solution, then adding the enterobacter peptides into the ethanol aqueous solution, stirring for 22min, and cooling to room temperature;
(4) freeze-drying the ethanol water solution containing the enterobacter peptide and the beta-cyclodextrin obtained in the step (3) for 11 hours;
(5) mixing the freeze-dried inclusion compound obtained in the step (4) with water-soluble starch, and then crushing to obtain a particle size of 72 meshes;
(6) mixing, and packaging to obtain soluble powder of enterobacter peptide.
Example 6:
a soluble powder containing enterobacter peptide comprises the following components in weight per 100g of medicine: 8g of enterobacter peptide, 15g of beta-cyclodextrin and the balance of water-soluble starch.
The enterobacter peptide is a metabolite of Escherichia coli ZNYT2, wherein the Escherichia coli ZNYT2 is preserved in the common microorganism center of China Committee for culture Collection of microorganisms, and the preservation unit is abbreviated as: CGMCC, storage unit address: west road No.1 hospital No. 3, north jing, chaoyang district, preservation date: 2016, 8, 23 days, accession number: CGMCC number 12902, taxonomic nomenclature: escherichia coli.
The preparation method of the soluble powder containing the enterobacter peptide comprises the following specific steps:
(1) preparing an ethanol aqueous solution with the volume fraction of 18%;
(2) weighing enterobacter peptide and beta-cyclodextrin according to the formula ratio, wherein the mass ratio of the beta-cyclodextrin to water in the ethanol water solution prepared in the step (1) is 1: 7;
(3) placing the ethanol aqueous solution prepared in the step (1) into a stirring tank, at the temperature of 56 ℃, dissolving beta-cyclodextrin into the ethanol aqueous solution under the stirring condition, adding the enterobacter peptides into the ethanol aqueous solution, stirring for 26min, and cooling to room temperature;
(4) carrying out freeze-drying treatment on the ethanol aqueous solution containing the enterobacter peptide and the beta-cyclodextrin obtained in the step (3) for 12 hours;
(5) mixing the freeze-dried inclusion compound obtained in the step (4) with water-soluble starch, and then crushing to obtain a particle size of 76 meshes;
(6) mixing, and packaging to obtain soluble powder of enterobacter peptide.
Example 7:
a soluble powder containing enterobacter peptide comprises the following components in weight per 100g of medicine: 10g of enterobacter peptide, 20g of beta-cyclodextrin and the balance of water-soluble starch.
The enterobacter peptide is a metabolite of Escherichia coli ZNYT2, wherein the Escherichia coli ZNYT2 is preserved in the common microorganism center of China Committee for culture Collection of microorganisms, and the preservation unit is abbreviated as: CGMCC, storage unit address: west road No.1 hospital No. 3, north jing, chaoyang district, preservation date: 2016, 8, 23 days, accession number: CGMCC number 12902, taxonomic nomenclature: escherichia coli.
The preparation method of the soluble powder containing the enterobacter peptide comprises the following specific steps:
(1) preparing an ethanol water solution with the volume fraction of 20%;
(2) weighing enterobacter peptide and beta-cyclodextrin according to the formula ratio, wherein the mass ratio of the beta-cyclodextrin to water in the ethanol water solution prepared in the step (1) is 1: 7;
(3) placing the ethanol aqueous solution prepared in the step (1) into a stirring tank, at the temperature of 60 ℃, dissolving beta-cyclodextrin into the ethanol aqueous solution under the stirring condition, adding the enterobacter peptides into the ethanol aqueous solution, stirring for 30min, and cooling to room temperature;
(4) carrying out freeze-drying treatment on the ethanol aqueous solution containing the enterobacter peptide and the beta-cyclodextrin obtained in the step (3) for 12 hours;
(5) mixing the freeze-dried inclusion compound obtained in the step (4) with water-soluble starch, and then crushing to obtain a powder with the granularity of 80 meshes;
(6) mixing, and packaging to obtain soluble powder of enterobacter peptide.
The enterobacter peptides can be produced by a conventional method using E.coli ZYT 2, and can also be produced by the following steps using E.coli ZYT 2 as described above:
(1) and (3) separation of strains: through the enrichment, primary screening and secondary screening of outdoor collected samples, the bacteriostatic substances generated by screening from the primary screened strains can well tolerate high temperature and protease treatment, and the strain S49-2 which has rapid growth and large and obvious bacteriostatic circle is named as probiotic escherichia coli ZNYT 2;
(2) mutagenesis of the strain: carrying out amplification culture on the separated original strain of the probiotic escherichia coli ZNYT2, preparing a bacterial suspension, carrying out mutagenesis on the strains in the bacterial suspension by using helium neon laser, carrying out culture and screening to select the strains with rapid growth and large diameter of a transparent ring, carrying out compound mutagenesis by using ultraviolet nitrosoguanidine, carrying out culture and primary screening to select the strains with rapid growth and large diameter of the transparent ring, and carrying out secondary screening to obtain a stable high-yield strain;
(3) expanded culture of strains
Performing strain activation, shake flask culture and seed tank culture on the stable high-yield Escherichia coli ZNYT2 obtained in the step (2) to obtain seed fermentation liquor;
(4) fermentation culture in fermentation tank
Inoculating the seed fermentation liquor obtained in the step (3) on a fermentation tank culture medium in a fermentation tank, and performing fermentation culture to obtain fermentation liquor;
(5) carrying out post-treatment on the fermentation liquor obtained in the step (4) to obtain enterobacter peptides
a. Double-effect concentration; concentrating under vacuum condition by using a double-effect separator;
b. alcohol precipitation: adjusting the alcohol content of the fermentation liquor after double-effect concentration to 65-85% in volume fraction, and carrying out alcohol precipitation at 4 ℃;
c. centrifuging: carrying out centrifugal separation on the fermentation liquor after alcohol precipitation, and collecting supernatant;
d. and (3) decoloring: the supernatant after centrifugation is decolorized by an alumina percolation column;
e. and (3) recovering alcohol: recovering ethanol in the decolorized fermentation liquor until no alcohol smell exists;
f. salting out: adding ammonium sulfate into the fermentation liquor after alcohol recovery, stirring while changing, continuing stirring for 1-2h after adding the ammonium sulfate, standing for 12-15h, centrifuging, collecting precipitate, and performing salting-out separation on the polypeptide by adopting a saturated ammonium sulfate solution method; according to the saturation solution table of ammonium sulfate, 767g of ammonium sulfate solid is added into 1L of fermentation liquor;
g. and (3) microfiltration: redissolving the collected salting-out precipitate by using an ethanol solution with the volume fraction of 20%, carrying out microfiltration on the redissolved solution by using a microfiltration membrane with the diameter of 0.45 mu m, and collecting a micro-filtrate;
h. and (3) column chromatography separation: performing column chromatography separation on the micro-filtrate by using a chromatographic column, and collecting eluent by adopting a gradient elution method;
i. and (3) ultrafiltration: ultrafiltering the eluate by 1000Da ultrafiltration membrane, and collecting the trapped fluid;
j. freeze-drying: and (4) carrying out low-temperature vacuum freeze drying on the ultrafiltered trapped fluid to obtain the pure product of the enterobacter peptide.
The chromatographic column used in the h step in the step (5) is a BPG200/500 chromatographic column.
The column chromatography separation in the step (5) in the step h comprises the following specific steps:
(1) washing the column with pure water until the baseline is balanced; buffer A Wash column 2 CV;
(2) loading a sample, wherein the loading amount is one time of the column volume;
(3) buffer A equilibrated column 3 CV;
(4) performing 0-100% linear gradient elution on Buffer B, observing the conductivity change and a spectrogram, and collecting a target substance peak;
(5) washing the column with Buffer B3 CV until the baseline and the conductance decrease to pure water conductance, and preparing for next sample loading;
buffer solution: BufferA: 1M/L sodium chloride; BufferB: pure water;
preparing a sample solution: the enterobacter peptides were dissolved in a 20% ethanol solution by volume fraction, and the conductance was adjusted to 55ms/cm with pharmaceutical grade sodium chloride.
The results of comparing the solubility of the enterobacter peptides in water with the enterobacter peptide soluble powder prepared in example 5 of the present invention are shown in table 1 and fig. 1.
From the solubility comparison test: the solubility of the enterobacter peptide in water is low and can be increased along with the increase of the pH value of the aqueous solution, the stability of the enterobacter peptide soluble powder is high, the solubility is obviously increased, and the pH value of the aqueous solution has little influence on the solubility.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various changes and modifications can be made without departing from the overall concept of the present invention, and these should also be considered as the protection scope of the present invention.
Claims (2)
1. A soluble powder comprising enterobacter peptides, characterized in that: the weight of each 100g of the medicine is as follows: 6g of enterobacter peptide, 12g of beta-cyclodextrin and the balance of water-soluble starch; the enterobacter peptide is a metabolite of Escherichia coli ZNYT2, and the Escherichia coli ZNYT2 is preserved in the common microorganism center of China Committee for culture Collection of microorganisms, wherein the preservation unit is abbreviated as: CGMCC, storage unit address: west road No.1 hospital No. 3, north jing, chaoyang district, preservation date: 2016, 8, 23 days, accession number: CGMCC number 12902, taxonomic nomenclature: escherichia coli.
2. The method for producing a soluble powder containing an enterobacter peptide according to claim 1, wherein: the method comprises the following specific steps:
(1) preparing ethanol water solution with volume fraction of 10-20%;
(2) weighing enterobacter peptide and beta-cyclodextrin according to the formula ratio, wherein the mass ratio of the beta-cyclodextrin to water in the ethanol water solution prepared in the step (1) is 1 (5-7);
(3) placing the ethanol aqueous solution prepared in the step (1) into a stirring tank, wherein the temperature is 40-60 ℃, under the stirring condition, firstly dissolving beta-cyclodextrin in the ethanol aqueous solution, then adding enterobacter peptides into the ethanol aqueous solution, stirring for 10-30min, and cooling to room temperature;
(4) freeze-drying the ethanol water solution containing the enterobacter peptide and the beta-cyclodextrin obtained in the step (3) for 8-12 h;
(5) mixing the freeze-dried inclusion compound obtained in the step (4) with water-soluble starch, and then crushing to obtain powder with the granularity of 60-80 meshes;
(6) mixing, and packaging to obtain soluble powder of enterobacter peptide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710985369.6A CN107519479B (en) | 2017-10-20 | 2017-10-20 | Soluble powder containing enterobacter peptide and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710985369.6A CN107519479B (en) | 2017-10-20 | 2017-10-20 | Soluble powder containing enterobacter peptide and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107519479A CN107519479A (en) | 2017-12-29 |
| CN107519479B true CN107519479B (en) | 2020-12-08 |
Family
ID=60684838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710985369.6A Active CN107519479B (en) | 2017-10-20 | 2017-10-20 | Soluble powder containing enterobacter peptide and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107519479B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110575532A (en) * | 2018-06-08 | 2019-12-17 | 上海莫息生物科技有限公司 | Nosiheptide soluble powder and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080200374A1 (en) * | 2005-03-09 | 2008-08-21 | Rutgers, The State University Of New Jersey | Mutational derivatives of microcin j25 |
| CN101584854A (en) * | 2008-05-22 | 2009-11-25 | 北京嘉事联博医药科技有限公司 | Romurtide cyclodextrin inclusion compound, preparation thereof and method for preparing same |
| CN106497859A (en) * | 2016-12-09 | 2017-03-15 | 中国科学院广州能源研究所 | A kind of method that utilization conductive carrier tames propanoic acid methanogen film |
-
2017
- 2017-10-20 CN CN201710985369.6A patent/CN107519479B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080200374A1 (en) * | 2005-03-09 | 2008-08-21 | Rutgers, The State University Of New Jersey | Mutational derivatives of microcin j25 |
| CN101584854A (en) * | 2008-05-22 | 2009-11-25 | 北京嘉事联博医药科技有限公司 | Romurtide cyclodextrin inclusion compound, preparation thereof and method for preparing same |
| CN106497859A (en) * | 2016-12-09 | 2017-03-15 | 中国科学院广州能源研究所 | A kind of method that utilization conductive carrier tames propanoic acid methanogen film |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107519479A (en) | 2017-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110903409B (en) | Millettia speciosa polysaccharide, preparation method and application thereof in antibacterial aspect | |
| CN106635924B (en) | Preparation and application of lactobacillus rhamnosus exopolysaccharide | |
| CN107721990B (en) | Marine fungus-derived isoindolinone compounds, preparation method thereof and application thereof in preparation of anti-inflammatory drugs | |
| US10835552B2 (en) | Method for preparing linseed polysaccharide having antiviral activity and immunological activity, and use of the linseed polysaccharide | |
| WO2020207048A1 (en) | Preparation method for and application of bacillus pumilus antibacterial active substance | |
| CN114806929A (en) | Lactobacillus reuteri LR4009 capable of highly producing reuterin and application thereof | |
| CN107519479B (en) | Soluble powder containing enterobacter peptide and preparation method thereof | |
| CN110642962B (en) | Separation and purification method of hybrid bean pectin polysaccharide | |
| CN104311645B (en) | Spirulina polypeptide P1 and its application with bacteriostatic activity | |
| CN105153321B (en) | A kind of fast separating process of the oligomeric sugar monomer of the lotus seeds with prebiotic effect | |
| CN111363056B (en) | Rhodopseudomonas palustris exopolysaccharide and preparation method and application thereof | |
| CN104277099A (en) | Preparation method and application of entomogenous fungus antibacterial peptide | |
| CN108503724A (en) | Chinese caterpillar fungus culture medium polysaccharide and its isolation and purification method and application | |
| CN103936827B (en) | Antibacterial tripeptides of a kind of leek seed and preparation method thereof and application | |
| CN113480672B (en) | Exopolysaccharide of bacillus and application thereof | |
| CN105483177A (en) | Preparing method of water insolubility exopolysaccharides of leuconostoc mesenteroides | |
| CN112458128B (en) | Application of marine halomonas extracellular polysaccharide in preparation of immunopotentiator | |
| CN101280333B (en) | Method for preparing penicillium antibacterial peptide from grey rose penicillium | |
| CN116694485B (en) | Application of colletotrichum gloeosporioides and extracellular polysaccharide thereof as plant immunity elicitor | |
| CN109576222A (en) | A kind of candidate stem cell culture medium | |
| CN109234333B (en) | Method for preparing high-immunocompetence dendrobium officinale endophytic fungi polysaccharide through liquid fermentation | |
| CN108641006B (en) | Method for extracting, separating and purifying polysaccharide from cordyceps militaris culture medium leftovers | |
| CN102115736B (en) | Purification method of plant chlorophyllase | |
| CN110484514A (en) | The method for isolating and purifying phage splitting liquid pnagus medius using two step salting-out extractions | |
| CN109400746B (en) | Eurycoma longifolia polysaccharide with immunoregulation and anti-erythrocyte hemolysis activity and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |